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Optimization of type 2 diabetes mellitus 
control in Egyptian patients
ABSTrACT
Background. Optimum management for a patient with 
type 2 diabetes mellitus (T2DM) requires periodic evalu-
ation and monitoring of the patient’s risk factors to 
measure its impact on different classes of treatment. 
Also the diabetes complications must be evaluated and 
initial review of drug history. This study aims to analyze 
clinical characteristics, risk factors, and contributions 
of each variable on predictive performances of each 
protocol used in the treatment of T2DM patients. 
Methods. A comparative description, a study of 2000 
Egyptian patients. Patients were categorized into eight 
groups according to the treatment protocol used. Mul-
tivariate logistic regression was applied to assess the 
probability of each protocol to reach target glycated 
hemoglobin A1c (hbA1c) in comparison to the standard 
protocol metformin + SU (protocol A) 
results. The proportion of patients in our study reach-
ing hbA1c ≤ 7% ranged between 48.9% in dipeptidyl 
peptidase-4 inhibitors (DPP-4 inhibitors) group (pro-
tocol h), and 59.2% in metformin + DPP-4 inhibitors 
group (protocol B). In subgroup analysis according 
to disease duration (≤ 8 years duration), mean hbA1c 
spanned from 7.4 ± 0.49% in SU monotherapy (proto-
col D) to 8.6 ± 0.5% in metformin + SU; the likelihood 
of reaching hbA1c > 7 was lower in the protocol A and 
protocol B.
Conclusion. Patients not controlled on metformin alone 
with lifestyle modification should be switched to either 
protocol A or protocol B based on the preferential clini-
cal outcome if there is no contraindication, as these 
two protocols are associated with the best result and 
a high percentage of patients reaching target hbA1c.
(Clin Diabetol 2020; 9; 6: 433–441)
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Introduction
Type 2 diabetes mellitus (T2DM) is considered one 
of the major worldwide public health problems. It is 
mainly a consequence of the currently observed bad 
lifestyle behavior such as sedentary life, fast food and 
obesity, which is considered an essential contributor 
to T2DM worldwide [1]. By 2030, it is expected that 
around half of the adult population in the world will 
be overweight (BMI 25–29.9 kg/m2) or obese (BMI 
> 30 kg/m2) [2]. Thus, diabetes prevalence is predicted 
to rise to 693 million worldwide by 2045 [3]. T2DM is 
associated with a large number of complications and 
increased mortality [4, 5], as it is the main cause of renal 
failure [6–8], blindness, and leg amputations [9]. Also, 
diabetes mellitus has of cardiovascular complications, 
the major cause of death in patients with diabetes [10]. 
So, patient quality of life reduces significantly with this 
disease, especially if uncontrolled, and life expectancy 
is decreased by, on average, eight years compared with 
healthy people [3].
The American Diabetes Association’s Standards 
of Medical Care in Diabetes [11] focuses on diet and 
other non-pharmacological measures for the manage-
ment of T2DM, but the concept of these measures is 
not applicable in many of primary health care systems 
[12, 13]. Optimum management for a patient with 
diabetes requires an initial evaluation of the patient’s 
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risk factors for careful selection of different classes of 
treatment. Additionally, diabetes complications, as well 
as medical history should be evaluated [14]. So far met-
formin is the first-line treatment for T2DM unless there are 
contraindications, either metformin alone or with lifestyle 
modifications or in combination with other agents [15]. In 
comparison with sulfonylureas (SUs), metformin as first-
line therapy has a good impact on target HbA1c, weight, 
and cardiovascular mortality [16]. However, choosing 
a second-line therapy is challenging, because it differs 
according to patient characteristics and risk factors.
A lot of studies suggests that each new class of 
treatment if added to metformin generally lowers 
HbA1c by approximately 0.7–1.0% [17]. If the HbA1c 
target is not achieved after approximately 3 months, 
a combination of metformin and any one of the pre-
ferred six treatment options should be considered: 
SU, thiazolidinedione, dipeptidyl peptidase 4 (DPP-4) 
inhibitor, sodium glucose cotransporter 2 (SGLT2) in-
hibitor, glucagon like peptide (GLP-1) receptor agonist, 
or basal insulin; the choice of agent to add is based 
mainly on the drug effects, side effects and patient 
factors. Nowadays, the choice of a second agent to 
add to metformin is controversial. Rather, drug choice 
is based on avoidance of side effects, particularly risk 
of hypoglycemia and weight gain, cost, and patient 
preference [18].
A study including 2677 adult American patients 
with self-reported T2DM called National Health and 
Nutrition Examination Survey showed that mean HbA1c 
was reduced with treatment with different classes, but 
still didn’t reach the recommended treatment target 
[19]. Additionally, the actual effectiveness in clinical 
practice is mostly unknown.
Aim of the study
Our study was designed to identify clinical charac-
teristics, risk factors affecting target goal control and 
likelihood of each protocol to achieve target HbA1c in 
unselected T2DM patients. 
Methods
A comparative descriptive, observational study. 
Representative sample of adult T2DM patients who 
received treatment at several diabetes outpatient clin-
ics were assessed to evaluate different treatments’ 
effects on HbA1c, the relationship between different 
treatments and patient characteristics, risk factors and 
proportion of diabetes complication in outpatient clin-
ics of the following hospitals (Ahmed Maher Hospital, 
National Diabetes Center, Alasr Elainy Hospital, Elde-
merdash Hospital and Elsalam Hospital) in the period 
from January 2017 to February 2019.
Patients received metformin (Glucophage, 500 and 
850 mg tablets, Bristol Myers Squibb, NY) as monotherapy 
(protocol C). During the 4-week run-in period, patients 
were treated with 500 to 2550 mg/day of metformin 
divided into one to three doses. The dose was adjusted 
during the first 3 weeks of the run-in to (1) achieve and 
maintain target fasting blood glucose (FBG) levels of 
90–126 mg/dL, or (2) the maximally tolerated dose, or (3) 
a maximum daily dose of 2550 mg. The patient’s met-
formin dose was not changed after the fourth week of the 
run-in period, unless a dose reduction was necessary for 
clinical reasons. At the end of the run-in period, patients 
who were not able to achieve the FBG target of 90–126 
mg/dL on metformin only were randomized to one of four 
treatment regimens: (1) metformin and biphasic insulin 
aspart (protocol E) (70% protaminated insulin aspart, 30% 
soluble insulin aspart, NovoLog Mix 70/30) administered 
within 10 min before the start of dinner; (2) metformin 
and Glibenclamide 10 mg twice daily (protocol A) or 
(3) metformin and sitagliptin (protocol B) 100 mg daily 
dose or (4) metformin + SU + insulin NPH (protocol F). 
The dose adjustments were based on twice-weekly self-
monitored blood glucose (SMBG) assessments. SU mono-
therapy (Glibenclamide) 10 mg twice daily (protocol D). 
DPP-4 inhibitors monotherapy (sitagliptin) 100 mg daily 
dose (protocol H). SU (Glibenclamide 10 mg twice daily) 
+ insulin NPH (protocol G). The starting insulin dose 
was 0.16 U/kg. During the first 4 weeks of treatment, 
the insulin dosage was adjusted by 2–6 U to achieve FBG 
levels of 90–126 mg/dL.
For all subjects in groups, patient education pro-
grams, and counseling with oral and printed material 
about types of food suitable for type 2 diabetes, lifestyle 
modifications, any potential dietary factors that may be 
harmful to patients, and the importance of adherence 
to medication and home self-measurement.
A total of 2000 Egyptian patients, who were cat-
egorized into eight groups according to the protocol 
used, were recruited. 
Patient data collection included standardized 
medical examinations, patient interviews, blood sam-
ple collection and medical history review. We analyzed 
age, sex, diabetes duration (DD), HbA1c, low-density 
lipoprotein (LDL), lipid-lowering medication (LW), 
systolic and diastolic blood pressure (BP), antihyper-
tensive medication, estimated glomerular filtration rate 
(eGFR), cumulative microalbuminuria, body mass index 
(BMI), smoking, physical activity (PA), and a history of 
cardiovascular disease (CVD) for each protocol group. 
We used cut-off ≤ 7% instead of < 7% as HbA1c 
goal in Egyptian outpatient clinics standard, since 
to most clinicians, 7% is the treatment goal (accord-
ing to hospitals protocols). A smoker was defined as 
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smoking one or more cigarettes per day, or who had 
stopped smoking within the past 3 months. Estimated 
GFR was calculated using the Modification of Diet in 
Renal Disease (MDRD) equation: 175 × serum creati-
nine/88.4 1.154 × age−0.203 for men, and: 175 × 
serum creatinine/88.4−1.154 × age−0.203 × 0.742 
for women [20]. Cumulative microalbuminuria was 
defined as urine albumin excretion > 20 mcg/min in 
two of three consecutive tests. History of CVD and CHD 
was defined as history of at least one CVD or CHD. 
Physical activity was defined according to the Center 
for Disease Control and Prevention (CDC): moderate 
physical activity — walking at a moderate or brisk pace 
of 3 to 4.5 mph on a level surface inside or outside; 
mild — walking at a pace of less than 3 to 4.5 mph; 
severe — race-walking and aerobic walking at a pace 
of 5 mph or faster [21]. The definition of T2DM used in 
this study was a patient treated with oral hypoglycemic 
agents (OHAs) only, or onset age of diabetes at the 
age of ≥ 40 years and treated with insulin combined 
with oral hypoglycemic agent. To ensure at least six 
months of continuous medication, enrolled were only 
patients treated in Egypt outpatient clinics who had 
filled at least six-monthly prescriptions.. One prescrip-
tion generally corresponds to one-month continuous 
treatment. Thus, six filled prescriptions correspond to 
at least six months of medication.
Statistical analysis
Continuous variables are expressed as mean ± 
standard deviation (SD) and ranges, and as medians 
when the data were nonparametric. Comparisons be-
tween two parallel groups with continuous data were 
performed using an independent t test, while similar 
non-parametric categorical data were compared using 
the chi-square test and non-parametric continuous data 
were compared using the Mann Whitney test. Univari-
ate and multivariate analyses were used to predict influ-
ence of clinical characteristics and protocol type on the 
likelihood of reaching HbA1c > 7.0% using metformin 
and SU as a reference. The confidence interval was set 
at 95%. Thus, the P value was considered significant at 
P < 0.05. Statistical analyses were conducted using the 
Statistical Package for the Social Sciences (IBM SPSS® 
25), and R program software version 9.2. 
Results
Treatment regimens
Of the 2000 patients treated with the most com-
mon prescribed treatment, 9.8% were treated with met-
formin monotherapy (protocol C), 9.2% SU monother-
apy (protocol D), 25.7% metformin + SU (protocol A), 
14.2% metformin + DPP-4 inhibitors (protocol B), 
10.6% metformin + insulin NPH (protocol E), 10.5% 
metformin + SU + insulin NPH (protocol F), 11.3% 
SU + insulin NPH (protocol G), 8.7% DPP-4 inhibitors 
monotherapy (protocol H).
Clinical characteristics
Age varied between 53.1 ± 7.1 and 57.2 ± 6.3 
years in the treatment groups; diabetes duration 7.2 
± 2.1–10.3 ± 2.1 years; BMI 26.9 ± 3.9–30.3 ± 5.8 
kg/m2; eGFR 52.1 ± 7.01–55.1 ± 9.3 ml/min/1.73 m2; 
proportion with cumulative microalbuminuria 23–33%; 
history of CVD 24.3–28.8% (Table 1). Patients on met-
formin + SU had the highest duration of diabetes, 
baseline HbA1c and proportion of smokers; patients 
on metformin monotherapy had a shorter duration of 
diabetes, a lower proportion of patients with micro-
albuminuria, and a lower proportion of patients with 
CVD than the other protocols. Patients on metformin 
+ SU + insulin NPH were older, had higher eGFR, and 
more frequent antihypertensive treatment; there were 
a higher proportion of women on all treatments. 
Treatment results
Comparing glycated hemoglobin A1c (HbA1c) be-
tween the groups, there were significant differences, as 
it ranged from 7.6 ± 0.49 in metformin + SU + insulin 
NPH (lowest) to 8.6 ± 5.3% in metformin + SU (high-
est), P < 0.0001. The proportion of patients reaching 
HbA1c ≤ 7% ranged between 48.9% in DPP-4 inhibi-
tors monotherapy, and 59.2% in metformin + DPP-4 
inhibitors. In a subgroup of newly diagnosed patients 
(≤ 8 years duration), mean HbA1c spanned from 7.4 ± 
0.49% in SU monotherapy, to 8.6 ± 0.5 in metformin + 
SU. Patient with diabetes duration > 8 years has HbA1c 
range from 7.57 ± 0.51 SU monotherapy to 8.65 ± 
0.53 in metformin + SU (Table 2). 
The percent of patients reaching targets for blood 
pressure and LDL ranged between 41.2% to 49.3% and 
23.5% to 36.1%, respectively (Table 2). Comparisons 
between men and women (Table 3) showed significant 
differences in the odds of obtaining HbA1c ≤ 7 in only 
two treatment groups (protocol A and B). There were 
slightly higher proportions of men among those who 
reached HbA1c ≤ 7% in all treatment groups. Differential 
impact of different variables on the likelihood of having 
HbA1c such as age, sex, use of lipid-lowering agents 
(lowest impact), physical activity, disease duration, 
body mass index, and estimated glomerular filtration 
rate (highest impact) is presented in Figures 1 and 2.
Data in Table 4 and Figure 3 give the likelihood of 
having HbA1c >7% in each group and the impact of 
each variable compared to patients on metformin + 
SU (reference). Patients on all other pharmacological 
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57.2 ± 6.353.1 ± 7.156.1 ± 7.553.5 ± 7.255.3 ± 7.155.7 ± 6.554.51 ± 6.854.53 ± 6.9Mean ± SDAge (years)
36.2/63.843.4/56.631.8/68.240.8/59.242.4/57.634.2/65.839.1/60.940.7/59.3%Gender
Male/female
7.5 ± 2.07.5 ± 2.47.3 ± 1.87.5 ± 2.77.6 ± 1.97.2 ± 2.18.7 ± 2.010.3 ± 2.1Mean ± SDDiabetes duration 
22.51616.820.417.92321.824.7%Smokers
29.1 ± 5.128.2 ± 4.728.8 ± 5.430.3 ± 5.826.9 ± 3.8928.8 ± 4.428.3 ± 4.927.9 ± 5.1Mean ± SDBMI [kg/m2]
















Means ± standard deviation (Mean ± SD) and proportions (%); BMI — body mass index; HbA1c — hemoglobin A1c; BP — blood pressure; eGFR — estimated 
glomerular filtration rate; CVD — cardiovascular disease; T2DM — type 2 diabetes mellitus

















7.7 ± 0.557.7 ± 0.517.6 ± 0.497.7 ± 0.617.6 ± 0.527.5 ± 0.68.2 ± 0.518.6 ± 0.53Mean ± SDHbA1c
48.951.857.353.65051.559.256.6%HbA1c ≤ 7
7.8 ±0.467.6 ± .527.7 ± 0.537.64 ± 0.517.57 ± .517.61 ± 0.58.31 ± 0.548.65 ± 
0..53
Mean ± SDHbA1c for diabetes 
duration (> 8 years)
7.6 ± 0.557.7 ± 0.57.5 ± 0.547.6 ± 0.53 
7.4 ± 0.4
7.6 ± .538.2 ± .528.6 ± 0.5Mean ± SDHbA1c for diabetes 
duration (≤ 8 years)
81 ± 8.782 ± 9.680.1 ± 9.181.5 ± 9.582 ± 9.281.5 ± 9.381.1 ± 8.982.3 ± 8.8Mean ± SDDiastolic
132.7± 
13.8






119.5± 26118.7 ± 
25.3
120.6 ± 24119 ± 23.6121 ± 25.6120 ± 25117 ± 24118.5± 25Mean ± SDLDL
2728.336.123.727.723.527.826.8%LDL < 100
35 ± 5.335.5 ± 5.336 ± 635 ± 5.436.1 ± 5.734 ± 6.134.8 ± 5.235 ± 5.6Mean ± SDHDL
HbA1c — hemoglobin A1c; LDL — low-density lipoprotein; HDL — high-density lipoprotein
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treatment regimens had a significantly higher likelihood 
of having HbA1c > 7%, ranging from) OR 2.89; 95% CI 
1.41–5.92( in metformin + SU + insulin NPH group to 
(OR 5.22; 95% CI 2.58–10.56( in DPP-4 inhibitors group, 
except for patients on metformin + DPP-4 inhibitors 
(OR 1.71; 95% CI 0.94–3.12) where the difference ver-
sus metformin + SU regimen was insignificant. Patients 
on metformin + DPP-4 inhibitors, in general, had the 
lowest likelihood of having HbA1c > 7%. Patients on 
SU monotherapy and DPP-4 inhibitors monotherapy 
had the lowest likelihood of reaching the target HbA1c 
≤ 7. The agreement between predicted data with real 
observation data is demonstrated in figure 3, indicating 
the internal validity of the developed regression model. 
Moreover, area under ROC curve was significantly 
higher (P < 0.0001), confirming the internal validity. 
Table 5 shows that our model had good predict-
ability and there is high concordance (0.96) between 
observed and predicted data. 
Discussion
The results of the present study proved that outpa-
tient clinics in Egypt apply world treatment guidelines 
in routine clinical care, as high percent of patients with 
T2DM (70.8%) were treated with metformin alone or 
in combination with other agents [22].
Fewer studies describing different treatment pro-
tocols according to different patient characteristics in 
real practice in Egypt are available, but there are many 
studies evaluating treatment effects of different T2DM 
medications. This study is a nation-wide cross‐sectional 
study analyzing clinical characteristics and impact or 
risk factors among T2DM patients with standard proto-
col (metformin and SU), as well as the most commonly 
used treatment regimens.
Most patients (> 25%) were prescribed sulfo-
nylureas add on to first-line metformin. This result 
matched to a population-based study that assessed 
which class of drugs was most commonly prescribed 
as second-line treatment added to metformin in the 
period between 2011 and 2015 where the results 
showed that these drugs are sulfonylureas [23]. Simi-
larly, the study of Zekarias et al. [24] found that more 
than 50% of patients were prescribed sulfonylureas. 
When comparing male and female sexes between 
each protocol, we found that almost all protocols 

















HbA1c mean M n 209 111 67 78 86 67 98 63
Mean ± SD 8.66 ± 0.53 8.2 ± 0.6 7.7 ± 0.51 7.6 ± 0.52 7.6 ± 0.54 7.7 ± 0.53 7.7 ± 0.52 7.6 ± 0.51
n 305 173 129 106 125 144 128 111
HbA1c mean W Mean ± SD 8.63 ± 0.5 8.4 ± 0.52 7.6 ± 0.53 7.7 ± 0.53 7.6 ± 0.53 7.5 ± 0.53 7.85 ± 0.6 7.7 ± 0.5
P value* 0.539 0.033 0.143 0.662 0.834 0.664 0.727 0.707
HbA1c ≤ 7 M % 63 67 53 56 60 58 52 57
HbA1c ≤ 7 W % 52 54 50 45 49 57 51.5 44
P value* 0.008 0.026 0.385 0.090 0.063 0.492 0.525 0.068
*P value of categorical data were performed using the chi-square test; M — men; W — women















0 50 100 150 200
2c  – df
2
c   P
250 350300
Figure 1. Contribution of each individual variable on predictive performance of the final multivariate model. Lw — lipid-lowering 
medication; PA — physical activity; DD — disease duration; BMI — body mass index; eGFR — estimated glomerular filtration rate
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showed marginally higher proportions of men reach-
ing HbA1c ≤ 7%, unlike a study of Ekström et al. [25] 
that found a proportion of women marginally higher 
with non-pharmacological treatment and metformin 
monotherapy. And there was a higher proportion of 
men reaching treatment goal on metformin + pre-
mixed analogues containing rapid-acting insulin and 
metformin + SU only. However, these differences were 
no statistically significant, except in only two protocols 














































Figure 2. Change in log (odds ratio) by changing each independent variable. Lw — lipid-lowering medication; PA — physical 
activity; DD — disease duration; BMI — body mass index; eGFR — estimated glomerular filtration rate
Table 4. Multivariate regression for significant variables and each protocol to estimate likelihood [(OR) with 95% CI] of 
having hbA1c > 7%
Clinical variable Univariate analysis Multivariate analysis
Regression coefficient SE P value Adjusted Or 95%CI P value
Age (years) 0.133 0.008 < 0.001 1.35 1.29–1.41 < 0.0001 (S)
BMI [kg/m2] 0.178 0.012 < 0.001 1.71 1.61–1.82 < 0.0001 (S)
eGFR [mL/min] 0.173 0.009 < 0.001 1.58 1.5–1.65 < 0.0001 (S)
Protocol
B –0.104 0.15 0.49 1.71 0.94–3.12 0.081 (NS)
C 0.205 0.17 0.22 3.92 1.96–7.81 0.0001 (S)
D 0.266 0.17 0.12 5.18 2.52–10.66 < 0.0001 (S)
E 0.124 0.16 0.45 4.41 2.17–8.96 < 0.0001 (S)
F -0.03 0.17 0.86 2.89 1.41–5.92 0.0038 (S)
G 0.195 0.16 0.22 5.8 2.91–11.54 < 0.0001 (S)
H 0.312 0.176 0.08 5.22 2.58–10.56 < 0.0001 (S)
Sex 0.34 0.093 < 0.0001 2.23 1.58–3.17 < 0.0001 (S)
PA level
High (PA) –0.32 0.13 0.013 0.37 0.23–0.6 < 0.0001 (S)
Low (PA) 0.23 0.1 0.028 1.93 1.32–2.83 0.0007 (S)
Disease duration (years) 0.24 0.021 < 0.0001 1.6 1.42–1.8 < 0.0001 (S)
Lipid-lowering agent use 0.0021 0.092 0.98 0.58 0.41–0.81 0.0016 (S)
OR — odd ratio; CI — confidence interval; HbA1c — hemoglobin A1c; eGFR — estimated glomerular filtration rate; BMI — body mass index; PA — physical 
activity
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tors). Thus, the clinical significance of these minor dif-
ferences is controversial.
In GRADE study [26] on 5000 patients categorized 
on the following medications: sulfonylureas, dipeptidyl 
peptidase 4 inhibitors, glucagon-like peptide 1 receptor 
agonists, and insulin as the second-line added to met-
formin found 64% of all participants reporting statin 
use but in our study, 58% of all participants reported 
statin use although new guidelines recommend statin 
for all patients with diabetes who are > 40 years of 
age, although without other cardiovascular risk. Unfor-
tunately, this percent indicates poor compliance with 
the guidelines [27].
According to ADA and the European Association 
for the Study of Diabetes, guidelines recommend 
starting basal insulin when HbA1c is > 9% [22]. Our 
findings from real practice does not support this rec-
ommendation, as there is high percent of patients with 
baseline HbA1c > 9 treated effectively with metformin 
and sulfonylurea protocol and metformin and DPP-4 
inhibitors protocols; this finding is similar to that of 
Wilding et al. [28]. This result may not be consistent 
with guidelines because a high proportion of patient 
have HbA1c > 9 not because of treatment resistance 
but due to poor adherence to treatment regimen. On 
other hand, mean reduction in HbA1c from baseline for 
those on metformin and sulfonylurea was significantly 
larger than all other protocols, so we conclude that 
treatment options for those with HbA1c  > 9% might 
not need to be limited only to insulin.
In comparison to study of Ekström et al. [25], 
insulin-based protocol achieved a higher proportion 
of patient HbA1c ≤7% , as clinician in Egypt use insulin 
as add on to metformin early in management. So, 
patient respond better than those who start insulin 
late. Also percent of patients achieving target LDL 
was significantly lower in our study, but our result 
matched with Ekström et al. [29], ADA, IDF and AACE 
guidelines that patient with metformin protocol had 
less history of CVD, microalbuminuria and percent of 
people achieving blood pressure goals as all groups 
ranged from 41.2–49.3%.
Yurgin et al. [30] found on German patients that 
around 50% of patients did not achieve target HbA1c 
< 6.5. However, this ratio is not applicable in our 
study as we reached in some protocols more than 
55% (metformin + SU, metformin + DPP-4 inhibitors 
and metformin + SU + insulin NPH. Although German 
study included higher number of participant, our study 
addressed risk factors and patient characteristics not 
studied in German study, such as diabetes duration, 
blood pressure, eGFR, LDL and body mass index. 
According to ADA and EASD, Swedish and inter-
national guidelines based on trials [31, 32], metformin 
is the first-line treatment when lifestyle and non-
pharmacological interventions are insufficient, and also 
a higher proportion of patient is treated with metform-
in monotherapy or in combination, so our real practice 
is consistent with this guidelines. But there are fewer 
studies which compare between different protocols 
and determine which protocol has the likelihood that 
patient achieve or not achieve the target; therefore, 
we in Table 4 found that only one protocol (metformin 
and DPP-4 inhibitors) was nonsignificant with standard 
protocol (metformin and SU) in likelihood of patient 
reaching HbA1c > 7 and all other protocols are signifi-
cant and odd ratio of patient reaching HbA1c > 7 ranges 
from 2.89–5.8. So, we strongly recommend metformin 
+ SU and metformin + DPP-4 inhibitors protocols, but 
we did not address cost, consequences, CVD exacerba-
tion, and incidence of hypoglycemia of these protocols 
to make a complete judgment. 
This study discusses the determinants of adequate 
glycemic control in T2DM population, explaining their 
underlying relative weights, and how they may affect 
the clinical decision regarding the choice of the an-
tihyperglycemic protocol on an individual basis. The 
main strength point in the current study is comparative 
analysis of eight different and commonly used proto-
cols in patients with diabetes as we study the effect 
of significant variables and how each variable, such as 
age, BMI, sex, physical activity, disease duration, lipid-
lowering agents and eGFR, can predict the outcome 
(Figs 1, 2). Thus, we conclude that good outcome does 
not dependent only on which protocol patient will be 
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treated but also these variables must be evaluated first 
and monitored.
The major strengths of this observational study are 
that patients were treated at hospital outpatient clinics 
nation-wide, representing the real-life situation in clini-
cal practice; also HbA1c analyses were quality assured.
Conclusion
The likelihood of reaching HbA1c > 7 is lower in the 
protocol A and protocol B, and other protocols are asso-
ciated with a significantly higher likelihood of reaching 
target HbA1c in comparison to protocol A. Significant 
variables, age, BMI, sex, physical activity, disease dura-
tion, lipid-lowering agents and eGFR if controlled, can 
improve treatment outcome significantly. 
Study limitations
There are also some limitations. Data from partici-
pating outpatient clinics may vary slightly in accuracy, 
although increased use of electronic dataset for data 
transfer can mitigate this problem. Also, around 20% 
of patients were excluded because of missing data. 
Controlling diet in this number of participants in each 
group is difficult and may cause slight changes in the 
response of each group to their medication. Blood lipid 
values were not measured at baseline. Instead, we used 
lipid-lowering medication (mostly statins) as a marker 
of the presence of dyslipidemia. Information regarding 
doses of drugs in protocols was not available, but the 
aim was to analyze the effect of clinical characteristics 
and risk factors on treatment outcome of each protocol 
with simulating in real practice.
Recommendations
Large, multicenter, observational studies in similar 
patient populations are needed to validate our conclusion. 
Compliance with ethical standards
Informed consent was obtained from each patient 
included in the study, and the study protocol was 
conducted in compliance with the 1975 Declaration of 
Helsinki and approved by Faculty of Pharmacy, Helwan 
University Ethical Committee.
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